# A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

> **NCT02087423** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 446 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** MEDI4736

## Key facts

- **NCT ID:** NCT02087423
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-25
- **Primary completion:** 2016-06-03
- **Final completion:** 2025-03-26
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02087423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02087423, "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02087423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*